Search Orphan Drug Designations and Approvals
-
Generic Name: | dalbavancin |
---|---|
Date Designated: | 03/30/2015 |
Orphan Designation: | Treatment of acute osteomyelitis in children (0 through 16 years of age) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Durata Therapeutics International B.V. Spaces Zuidas II, Kantoor 4.03 Amsterdam Netherlands The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-